nodes	percent_of_prediction	percent_of_DWPC	metapath
Salbutamol—CYP3A4—Rosuvastatin—atherosclerosis	0.0923	0.211	CbGbCtD
Salbutamol—CYP3A4—Ezetimibe—atherosclerosis	0.0923	0.211	CbGbCtD
Salbutamol—CYP3A4—Simvastatin—atherosclerosis	0.0858	0.196	CbGbCtD
Salbutamol—CYP3A4—Pravastatin—atherosclerosis	0.084	0.192	CbGbCtD
Salbutamol—CYP3A4—Lovastatin—atherosclerosis	0.084	0.192	CbGbCtD
Salbutamol—Clenbuterol—TNF—atherosclerosis	0.00177	0.704	CrCbGaD
Salbutamol—Hypoaesthesia—Pravastatin—atherosclerosis	0.00127	0.00258	CcSEcCtD
Salbutamol—Flatulence—Ezetimibe—atherosclerosis	0.00127	0.00258	CcSEcCtD
Salbutamol—Pharyngitis—Pravastatin—atherosclerosis	0.00127	0.00257	CcSEcCtD
Salbutamol—Chills—Simvastatin—atherosclerosis	0.00127	0.00257	CcSEcCtD
Salbutamol—Muscle spasms—Lovastatin—atherosclerosis	0.00127	0.00256	CcSEcCtD
Salbutamol—Infection—Rosuvastatin—atherosclerosis	0.00126	0.00255	CcSEcCtD
Salbutamol—Back pain—Ezetimibe—atherosclerosis	0.00125	0.00253	CcSEcCtD
Salbutamol—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00124	0.00252	CcSEcCtD
Salbutamol—Muscle spasms—Ezetimibe—atherosclerosis	0.00124	0.00251	CcSEcCtD
Salbutamol—Mental disorder—Simvastatin—atherosclerosis	0.00124	0.00251	CcSEcCtD
Salbutamol—Tremor—Lovastatin—atherosclerosis	0.00123	0.0025	CcSEcCtD
Salbutamol—Ill-defined disorder—Lovastatin—atherosclerosis	0.00122	0.00247	CcSEcCtD
Salbutamol—Flatulence—Simvastatin—atherosclerosis	0.00121	0.00246	CcSEcCtD
Salbutamol—Tinnitus—Niacin—atherosclerosis	0.00121	0.00245	CcSEcCtD
Salbutamol—Dysgeusia—Simvastatin—atherosclerosis	0.00121	0.00244	CcSEcCtD
Salbutamol—Flushing—Niacin—atherosclerosis	0.00121	0.00244	CcSEcCtD
Salbutamol—Angioedema—Lovastatin—atherosclerosis	0.0012	0.00244	CcSEcCtD
Salbutamol—Ill-defined disorder—Ezetimibe—atherosclerosis	0.0012	0.00243	CcSEcCtD
Salbutamol—Tinnitus—Pravastatin—atherosclerosis	0.00119	0.00241	CcSEcCtD
Salbutamol—Malaise—Lovastatin—atherosclerosis	0.00119	0.0024	CcSEcCtD
Salbutamol—Cardiac disorder—Pravastatin—atherosclerosis	0.00119	0.0024	CcSEcCtD
Salbutamol—Flushing—Pravastatin—atherosclerosis	0.00119	0.0024	CcSEcCtD
Salbutamol—Muscle spasms—Simvastatin—atherosclerosis	0.00118	0.0024	CcSEcCtD
Salbutamol—Vertigo—Lovastatin—atherosclerosis	0.00118	0.00239	CcSEcCtD
Salbutamol—Angioedema—Ezetimibe—atherosclerosis	0.00118	0.00239	CcSEcCtD
Salbutamol—Angiopathy—Niacin—atherosclerosis	0.00118	0.00239	CcSEcCtD
Salbutamol—Chills—Niacin—atherosclerosis	0.00117	0.00236	CcSEcCtD
Salbutamol—Malaise—Ezetimibe—atherosclerosis	0.00116	0.00236	CcSEcCtD
Salbutamol—Arrhythmia—Niacin—atherosclerosis	0.00116	0.00235	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00116	0.00234	CcSEcCtD
Salbutamol—Tremor—Simvastatin—atherosclerosis	0.00115	0.00234	CcSEcCtD
Salbutamol—Chills—Pravastatin—atherosclerosis	0.00115	0.00232	CcSEcCtD
Salbutamol—Insomnia—Rosuvastatin—atherosclerosis	0.00115	0.00232	CcSEcCtD
Salbutamol—Ill-defined disorder—Simvastatin—atherosclerosis	0.00114	0.00231	CcSEcCtD
Salbutamol—Arrhythmia—Pravastatin—atherosclerosis	0.00114	0.00231	CcSEcCtD
Salbutamol—Palpitations—Ezetimibe—atherosclerosis	0.00114	0.00231	CcSEcCtD
Salbutamol—Paraesthesia—Rosuvastatin—atherosclerosis	0.00114	0.0023	CcSEcCtD
Salbutamol—Malnutrition—Niacin—atherosclerosis	0.00113	0.00229	CcSEcCtD
Salbutamol—Cough—Ezetimibe—atherosclerosis	0.00113	0.00228	CcSEcCtD
Salbutamol—Angioedema—Simvastatin—atherosclerosis	0.00113	0.00228	CcSEcCtD
Salbutamol—Chest pain—Lovastatin—atherosclerosis	0.00112	0.00227	CcSEcCtD
Salbutamol—Myalgia—Lovastatin—atherosclerosis	0.00112	0.00227	CcSEcCtD
Salbutamol—Arthralgia—Lovastatin—atherosclerosis	0.00112	0.00227	CcSEcCtD
Salbutamol—Anxiety—Lovastatin—atherosclerosis	0.00112	0.00226	CcSEcCtD
Salbutamol—Dyspepsia—Rosuvastatin—atherosclerosis	0.00112	0.00226	CcSEcCtD
Salbutamol—Hypertension—Ezetimibe—atherosclerosis	0.00111	0.00226	CcSEcCtD
Salbutamol—Flatulence—Niacin—atherosclerosis	0.00111	0.00226	CcSEcCtD
Salbutamol—Malaise—Simvastatin—atherosclerosis	0.00111	0.00225	CcSEcCtD
Salbutamol—Tension—Niacin—atherosclerosis	0.00111	0.00225	CcSEcCtD
Salbutamol—Discomfort—Lovastatin—atherosclerosis	0.00111	0.00224	CcSEcCtD
Salbutamol—Vertigo—Simvastatin—atherosclerosis	0.00111	0.00224	CcSEcCtD
Salbutamol—Arthralgia—Ezetimibe—atherosclerosis	0.0011	0.00223	CcSEcCtD
Salbutamol—Myalgia—Ezetimibe—atherosclerosis	0.0011	0.00223	CcSEcCtD
Salbutamol—Chest pain—Ezetimibe—atherosclerosis	0.0011	0.00223	CcSEcCtD
Salbutamol—Nervousness—Niacin—atherosclerosis	0.0011	0.00222	CcSEcCtD
Salbutamol—Flatulence—Pravastatin—atherosclerosis	0.0011	0.00222	CcSEcCtD
Salbutamol—Dry mouth—Lovastatin—atherosclerosis	0.0011	0.00222	CcSEcCtD
Salbutamol—Tension—Pravastatin—atherosclerosis	0.00109	0.00221	CcSEcCtD
Salbutamol—Dysgeusia—Pravastatin—atherosclerosis	0.00109	0.00221	CcSEcCtD
Salbutamol—Muscle spasms—Niacin—atherosclerosis	0.00109	0.0022	CcSEcCtD
Salbutamol—Discomfort—Ezetimibe—atherosclerosis	0.00109	0.0022	CcSEcCtD
Salbutamol—Pain—Rosuvastatin—atherosclerosis	0.00108	0.00219	CcSEcCtD
Salbutamol—Constipation—Rosuvastatin—atherosclerosis	0.00108	0.00219	CcSEcCtD
Salbutamol—Nervousness—Pravastatin—atherosclerosis	0.00108	0.00219	CcSEcCtD
Salbutamol—Dry mouth—Ezetimibe—atherosclerosis	0.00108	0.00218	CcSEcCtD
Salbutamol—Anaphylactic shock—Lovastatin—atherosclerosis	0.00107	0.00217	CcSEcCtD
Salbutamol—Muscle spasms—Pravastatin—atherosclerosis	0.00107	0.00217	CcSEcCtD
Salbutamol—Infection—Lovastatin—atherosclerosis	0.00107	0.00216	CcSEcCtD
Salbutamol—Anaphylactic shock—Ezetimibe—atherosclerosis	0.00105	0.00213	CcSEcCtD
Salbutamol—Myalgia—Simvastatin—atherosclerosis	0.00105	0.00212	CcSEcCtD
Salbutamol—Chest pain—Simvastatin—atherosclerosis	0.00105	0.00212	CcSEcCtD
Salbutamol—Arthralgia—Simvastatin—atherosclerosis	0.00105	0.00212	CcSEcCtD
Salbutamol—Infection—Ezetimibe—atherosclerosis	0.00105	0.00212	CcSEcCtD
Salbutamol—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00104	0.00211	CcSEcCtD
Salbutamol—Anxiety—Simvastatin—atherosclerosis	0.00104	0.00211	CcSEcCtD
Salbutamol—Tremor—Pravastatin—atherosclerosis	0.00104	0.00211	CcSEcCtD
Salbutamol—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00104	0.0021	CcSEcCtD
Salbutamol—Discomfort—Simvastatin—atherosclerosis	0.00104	0.0021	CcSEcCtD
Salbutamol—Nervous system disorder—Ezetimibe—atherosclerosis	0.00103	0.00209	CcSEcCtD
Salbutamol—Angioedema—Niacin—atherosclerosis	0.00103	0.00209	CcSEcCtD
Salbutamol—Ill-defined disorder—Pravastatin—atherosclerosis	0.00103	0.00209	CcSEcCtD
Salbutamol—Anorexia—Lovastatin—atherosclerosis	0.00102	0.00207	CcSEcCtD
Salbutamol—Skin disorder—Ezetimibe—atherosclerosis	0.00102	0.00207	CcSEcCtD
Salbutamol—Angioedema—Pravastatin—atherosclerosis	0.00102	0.00206	CcSEcCtD
Salbutamol—Vertigo—Niacin—atherosclerosis	0.00102	0.00206	CcSEcCtD
Salbutamol—Syncope—Niacin—atherosclerosis	0.00101	0.00205	CcSEcCtD
Salbutamol—Urticaria—Rosuvastatin—atherosclerosis	0.00101	0.00204	CcSEcCtD
Salbutamol—Anaphylactic shock—Simvastatin—atherosclerosis	0.001	0.00203	CcSEcCtD
Salbutamol—Oedema—Simvastatin—atherosclerosis	0.001	0.00203	CcSEcCtD
Salbutamol—Malaise—Pravastatin—atherosclerosis	0.001	0.00203	CcSEcCtD
Salbutamol—Abdominal pain—Rosuvastatin—atherosclerosis	0.001	0.00203	CcSEcCtD
Salbutamol—Vertigo—Pravastatin—atherosclerosis	0.001	0.00202	CcSEcCtD
Salbutamol—Palpitations—Niacin—atherosclerosis	0.000999	0.00202	CcSEcCtD
Salbutamol—Infection—Simvastatin—atherosclerosis	0.000998	0.00202	CcSEcCtD
Salbutamol—Loss of consciousness—Niacin—atherosclerosis	0.000994	0.00201	CcSEcCtD
Salbutamol—Cough—Niacin—atherosclerosis	0.000987	0.002	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000979	0.00198	CcSEcCtD
Salbutamol—Insomnia—Lovastatin—atherosclerosis	0.000972	0.00197	CcSEcCtD
Salbutamol—Cough—Pravastatin—atherosclerosis	0.000971	0.00197	CcSEcCtD
Salbutamol—Paraesthesia—Lovastatin—atherosclerosis	0.000965	0.00195	CcSEcCtD
Salbutamol—Arthralgia—Niacin—atherosclerosis	0.000963	0.00195	CcSEcCtD
Salbutamol—Myalgia—Niacin—atherosclerosis	0.000963	0.00195	CcSEcCtD
Salbutamol—Hypertension—Pravastatin—atherosclerosis	0.000961	0.00195	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00096	0.00194	CcSEcCtD
Salbutamol—Anorexia—Simvastatin—atherosclerosis	0.000958	0.00194	CcSEcCtD
Salbutamol—Dyspnoea—Lovastatin—atherosclerosis	0.000958	0.00194	CcSEcCtD
Salbutamol—Insomnia—Ezetimibe—atherosclerosis	0.000953	0.00193	CcSEcCtD
Salbutamol—Arthralgia—Pravastatin—atherosclerosis	0.000948	0.00192	CcSEcCtD
Salbutamol—Chest pain—Pravastatin—atherosclerosis	0.000948	0.00192	CcSEcCtD
Salbutamol—Myalgia—Pravastatin—atherosclerosis	0.000948	0.00192	CcSEcCtD
Salbutamol—Paraesthesia—Ezetimibe—atherosclerosis	0.000946	0.00192	CcSEcCtD
Salbutamol—Dyspepsia—Lovastatin—atherosclerosis	0.000946	0.00191	CcSEcCtD
Salbutamol—Anxiety—Pravastatin—atherosclerosis	0.000944	0.00191	CcSEcCtD
Salbutamol—Dry mouth—Niacin—atherosclerosis	0.000941	0.00191	CcSEcCtD
Salbutamol—Dyspnoea—Ezetimibe—atherosclerosis	0.000939	0.0019	CcSEcCtD
Salbutamol—Discomfort—Pravastatin—atherosclerosis	0.000936	0.0019	CcSEcCtD
Salbutamol—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000934	0.00189	CcSEcCtD
Salbutamol—Decreased appetite—Lovastatin—atherosclerosis	0.000934	0.00189	CcSEcCtD
Salbutamol—Dyspepsia—Ezetimibe—atherosclerosis	0.000928	0.00188	CcSEcCtD
Salbutamol—Fatigue—Lovastatin—atherosclerosis	0.000926	0.00188	CcSEcCtD
Salbutamol—Anaphylactic shock—Niacin—atherosclerosis	0.000923	0.00187	CcSEcCtD
Salbutamol—Oedema—Niacin—atherosclerosis	0.000923	0.00187	CcSEcCtD
Salbutamol—Constipation—Lovastatin—atherosclerosis	0.000919	0.00186	CcSEcCtD
Salbutamol—Pain—Lovastatin—atherosclerosis	0.000919	0.00186	CcSEcCtD
Salbutamol—Decreased appetite—Ezetimibe—atherosclerosis	0.000916	0.00185	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000916	0.00185	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00091	0.00184	CcSEcCtD
Salbutamol—Asthenia—Rosuvastatin—atherosclerosis	0.00091	0.00184	CcSEcCtD
Salbutamol—Insomnia—Simvastatin—atherosclerosis	0.000909	0.00184	CcSEcCtD
Salbutamol—Anaphylactic shock—Pravastatin—atherosclerosis	0.000909	0.00184	CcSEcCtD
Salbutamol—Oedema—Pravastatin—atherosclerosis	0.000909	0.00184	CcSEcCtD
Salbutamol—Fatigue—Ezetimibe—atherosclerosis	0.000909	0.00184	CcSEcCtD
Salbutamol—Shock—Niacin—atherosclerosis	0.000908	0.00184	CcSEcCtD
Salbutamol—Infection—Pravastatin—atherosclerosis	0.000903	0.00183	CcSEcCtD
Salbutamol—Paraesthesia—Simvastatin—atherosclerosis	0.000902	0.00183	CcSEcCtD
Salbutamol—Constipation—Ezetimibe—atherosclerosis	0.000901	0.00182	CcSEcCtD
Salbutamol—Pain—Ezetimibe—atherosclerosis	0.000901	0.00182	CcSEcCtD
Salbutamol—Tachycardia—Niacin—atherosclerosis	0.000901	0.00182	CcSEcCtD
Salbutamol—Pruritus—Rosuvastatin—atherosclerosis	0.000897	0.00182	CcSEcCtD
Salbutamol—Skin disorder—Niacin—atherosclerosis	0.000896	0.00181	CcSEcCtD
Salbutamol—Dyspnoea—Simvastatin—atherosclerosis	0.000896	0.00181	CcSEcCtD
Salbutamol—Hyperhidrosis—Niacin—atherosclerosis	0.000892	0.00181	CcSEcCtD
Salbutamol—Feeling abnormal—Lovastatin—atherosclerosis	0.000885	0.00179	CcSEcCtD
Salbutamol—Dyspepsia—Simvastatin—atherosclerosis	0.000885	0.00179	CcSEcCtD
Salbutamol—Anorexia—Niacin—atherosclerosis	0.00088	0.00178	CcSEcCtD
Salbutamol—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000879	0.00178	CcSEcCtD
Salbutamol—Hyperhidrosis—Pravastatin—atherosclerosis	0.000878	0.00178	CcSEcCtD
Salbutamol—Decreased appetite—Simvastatin—atherosclerosis	0.000874	0.00177	CcSEcCtD
Salbutamol—Feeling abnormal—Ezetimibe—atherosclerosis	0.000868	0.00176	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000868	0.00176	CcSEcCtD
Salbutamol—Diarrhoea—Rosuvastatin—atherosclerosis	0.000867	0.00176	CcSEcCtD
Salbutamol—Fatigue—Simvastatin—atherosclerosis	0.000866	0.00175	CcSEcCtD
Salbutamol—Anorexia—Pravastatin—atherosclerosis	0.000866	0.00175	CcSEcCtD
Salbutamol—Hypotension—Niacin—atherosclerosis	0.000862	0.00175	CcSEcCtD
Salbutamol—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000862	0.00174	CcSEcCtD
Salbutamol—Pain—Simvastatin—atherosclerosis	0.000859	0.00174	CcSEcCtD
Salbutamol—Constipation—Simvastatin—atherosclerosis	0.000859	0.00174	CcSEcCtD
Salbutamol—Urticaria—Lovastatin—atherosclerosis	0.000854	0.00173	CcSEcCtD
Salbutamol—Abdominal pain—Lovastatin—atherosclerosis	0.000849	0.00172	CcSEcCtD
Salbutamol—Body temperature increased—Lovastatin—atherosclerosis	0.000849	0.00172	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000841	0.0017	CcSEcCtD
Salbutamol—Dizziness—Rosuvastatin—atherosclerosis	0.000838	0.0017	CcSEcCtD
Salbutamol—Urticaria—Ezetimibe—atherosclerosis	0.000837	0.00169	CcSEcCtD
Salbutamol—Insomnia—Niacin—atherosclerosis	0.000835	0.00169	CcSEcCtD
Salbutamol—Abdominal pain—Ezetimibe—atherosclerosis	0.000833	0.00169	CcSEcCtD
Salbutamol—Body temperature increased—Ezetimibe—atherosclerosis	0.000833	0.00169	CcSEcCtD
Salbutamol—Paraesthesia—Niacin—atherosclerosis	0.000829	0.00168	CcSEcCtD
Salbutamol—Feeling abnormal—Simvastatin—atherosclerosis	0.000828	0.00168	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000828	0.00168	CcSEcCtD
Salbutamol—Dyspnoea—Niacin—atherosclerosis	0.000823	0.00167	CcSEcCtD
Salbutamol—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000822	0.00166	CcSEcCtD
Salbutamol—Insomnia—Pravastatin—atherosclerosis	0.000822	0.00166	CcSEcCtD
Salbutamol—Somnolence—Niacin—atherosclerosis	0.00082	0.00166	CcSEcCtD
Salbutamol—Paraesthesia—Pravastatin—atherosclerosis	0.000816	0.00165	CcSEcCtD
Salbutamol—Dyspepsia—Niacin—atherosclerosis	0.000812	0.00164	CcSEcCtD
Salbutamol—Dyspnoea—Pravastatin—atherosclerosis	0.00081	0.00164	CcSEcCtD
Salbutamol—Decreased appetite—Niacin—atherosclerosis	0.000802	0.00162	CcSEcCtD
Salbutamol—Dyspepsia—Pravastatin—atherosclerosis	0.0008	0.00162	CcSEcCtD
Salbutamol—Rash—Rosuvastatin—atherosclerosis	0.000799	0.00162	CcSEcCtD
Salbutamol—Dermatitis—Rosuvastatin—atherosclerosis	0.000799	0.00162	CcSEcCtD
Salbutamol—Urticaria—Simvastatin—atherosclerosis	0.000798	0.00162	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Niacin—atherosclerosis	0.000797	0.00161	CcSEcCtD
Salbutamol—Body temperature increased—Simvastatin—atherosclerosis	0.000794	0.00161	CcSEcCtD
Salbutamol—Abdominal pain—Simvastatin—atherosclerosis	0.000794	0.00161	CcSEcCtD
Salbutamol—Headache—Rosuvastatin—atherosclerosis	0.000794	0.00161	CcSEcCtD
Salbutamol—Hypersensitivity—Lovastatin—atherosclerosis	0.000792	0.0016	CcSEcCtD
Salbutamol—Decreased appetite—Pravastatin—atherosclerosis	0.00079	0.0016	CcSEcCtD
Salbutamol—Pain—Niacin—atherosclerosis	0.000789	0.0016	CcSEcCtD
Salbutamol—Fatigue—Pravastatin—atherosclerosis	0.000783	0.00159	CcSEcCtD
Salbutamol—Pain—Pravastatin—atherosclerosis	0.000777	0.00157	CcSEcCtD
Salbutamol—Constipation—Pravastatin—atherosclerosis	0.000777	0.00157	CcSEcCtD
Salbutamol—Hypersensitivity—Ezetimibe—atherosclerosis	0.000776	0.00157	CcSEcCtD
Salbutamol—Asthenia—Lovastatin—atherosclerosis	0.000771	0.00156	CcSEcCtD
Salbutamol—Pruritus—Lovastatin—atherosclerosis	0.00076	0.00154	CcSEcCtD
Salbutamol—Asthenia—Ezetimibe—atherosclerosis	0.000756	0.00153	CcSEcCtD
Salbutamol—Gastrointestinal pain—Niacin—atherosclerosis	0.000755	0.00153	CcSEcCtD
Salbutamol—Nausea—Rosuvastatin—atherosclerosis	0.000753	0.00152	CcSEcCtD
Salbutamol—Feeling abnormal—Pravastatin—atherosclerosis	0.000749	0.00152	CcSEcCtD
Salbutamol—Pruritus—Ezetimibe—atherosclerosis	0.000746	0.00151	CcSEcCtD
Salbutamol—Epinephrine—TNF—atherosclerosis	0.000743	0.296	CrCbGaD
Salbutamol—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000743	0.0015	CcSEcCtD
Salbutamol—Hypersensitivity—Simvastatin—atherosclerosis	0.00074	0.0015	CcSEcCtD
Salbutamol—Diarrhoea—Lovastatin—atherosclerosis	0.000735	0.00149	CcSEcCtD
Salbutamol—Urticaria—Niacin—atherosclerosis	0.000733	0.00148	CcSEcCtD
Salbutamol—Body temperature increased—Niacin—atherosclerosis	0.000729	0.00148	CcSEcCtD
Salbutamol—Abdominal pain—Niacin—atherosclerosis	0.000729	0.00148	CcSEcCtD
Salbutamol—Urticaria—Pravastatin—atherosclerosis	0.000722	0.00146	CcSEcCtD
Salbutamol—Asthenia—Simvastatin—atherosclerosis	0.000721	0.00146	CcSEcCtD
Salbutamol—Diarrhoea—Ezetimibe—atherosclerosis	0.000721	0.00146	CcSEcCtD
Salbutamol—Abdominal pain—Pravastatin—atherosclerosis	0.000718	0.00145	CcSEcCtD
Salbutamol—Body temperature increased—Pravastatin—atherosclerosis	0.000718	0.00145	CcSEcCtD
Salbutamol—Pruritus—Simvastatin—atherosclerosis	0.000711	0.00144	CcSEcCtD
Salbutamol—Dizziness—Lovastatin—atherosclerosis	0.00071	0.00144	CcSEcCtD
Salbutamol—Dizziness—Ezetimibe—atherosclerosis	0.000697	0.00141	CcSEcCtD
Salbutamol—Diarrhoea—Simvastatin—atherosclerosis	0.000688	0.00139	CcSEcCtD
Salbutamol—Vomiting—Lovastatin—atherosclerosis	0.000683	0.00138	CcSEcCtD
Salbutamol—Hypersensitivity—Niacin—atherosclerosis	0.00068	0.00138	CcSEcCtD
Salbutamol—Rash—Lovastatin—atherosclerosis	0.000677	0.00137	CcSEcCtD
Salbutamol—Dermatitis—Lovastatin—atherosclerosis	0.000677	0.00137	CcSEcCtD
Salbutamol—Headache—Lovastatin—atherosclerosis	0.000673	0.00136	CcSEcCtD
Salbutamol—Vomiting—Ezetimibe—atherosclerosis	0.00067	0.00136	CcSEcCtD
Salbutamol—Hypersensitivity—Pravastatin—atherosclerosis	0.000669	0.00136	CcSEcCtD
Salbutamol—Dizziness—Simvastatin—atherosclerosis	0.000665	0.00135	CcSEcCtD
Salbutamol—Rash—Ezetimibe—atherosclerosis	0.000664	0.00135	CcSEcCtD
Salbutamol—Dermatitis—Ezetimibe—atherosclerosis	0.000664	0.00134	CcSEcCtD
Salbutamol—Asthenia—Niacin—atherosclerosis	0.000662	0.00134	CcSEcCtD
Salbutamol—Headache—Ezetimibe—atherosclerosis	0.00066	0.00134	CcSEcCtD
Salbutamol—Pruritus—Niacin—atherosclerosis	0.000653	0.00132	CcSEcCtD
Salbutamol—Asthenia—Pravastatin—atherosclerosis	0.000652	0.00132	CcSEcCtD
Salbutamol—Pruritus—Pravastatin—atherosclerosis	0.000643	0.0013	CcSEcCtD
Salbutamol—Vomiting—Simvastatin—atherosclerosis	0.000639	0.00129	CcSEcCtD
Salbutamol—Nausea—Lovastatin—atherosclerosis	0.000638	0.00129	CcSEcCtD
Salbutamol—Rash—Simvastatin—atherosclerosis	0.000634	0.00128	CcSEcCtD
Salbutamol—Dermatitis—Simvastatin—atherosclerosis	0.000633	0.00128	CcSEcCtD
Salbutamol—Diarrhoea—Niacin—atherosclerosis	0.000631	0.00128	CcSEcCtD
Salbutamol—Headache—Simvastatin—atherosclerosis	0.00063	0.00127	CcSEcCtD
Salbutamol—Nausea—Ezetimibe—atherosclerosis	0.000626	0.00127	CcSEcCtD
Salbutamol—Diarrhoea—Pravastatin—atherosclerosis	0.000622	0.00126	CcSEcCtD
Salbutamol—Dizziness—Niacin—atherosclerosis	0.00061	0.00124	CcSEcCtD
Salbutamol—Dizziness—Pravastatin—atherosclerosis	0.000601	0.00122	CcSEcCtD
Salbutamol—Nausea—Simvastatin—atherosclerosis	0.000597	0.00121	CcSEcCtD
Salbutamol—Vomiting—Niacin—atherosclerosis	0.000587	0.00119	CcSEcCtD
Salbutamol—Rash—Niacin—atherosclerosis	0.000582	0.00118	CcSEcCtD
Salbutamol—Dermatitis—Niacin—atherosclerosis	0.000581	0.00118	CcSEcCtD
Salbutamol—Headache—Niacin—atherosclerosis	0.000578	0.00117	CcSEcCtD
Salbutamol—Vomiting—Pravastatin—atherosclerosis	0.000578	0.00117	CcSEcCtD
Salbutamol—Rash—Pravastatin—atherosclerosis	0.000573	0.00116	CcSEcCtD
Salbutamol—Dermatitis—Pravastatin—atherosclerosis	0.000572	0.00116	CcSEcCtD
Salbutamol—Headache—Pravastatin—atherosclerosis	0.000569	0.00115	CcSEcCtD
Salbutamol—Nausea—Niacin—atherosclerosis	0.000548	0.00111	CcSEcCtD
Salbutamol—Nausea—Pravastatin—atherosclerosis	0.00054	0.00109	CcSEcCtD
Salbutamol—ADRB2—Signaling by GPCR—UTS2—atherosclerosis	0.000109	0.00167	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—EDN1—atherosclerosis	0.000108	0.00166	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—CCL5—atherosclerosis	0.000108	0.00165	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—CNR2—atherosclerosis	0.000107	0.00164	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—F2—atherosclerosis	0.000107	0.00164	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CX3CR1—atherosclerosis	0.000107	0.00164	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CASR—atherosclerosis	0.000107	0.00164	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—EDN1—atherosclerosis	0.000106	0.00163	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—CCL5—atherosclerosis	0.000105	0.00162	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CX3CL1—atherosclerosis	0.000105	0.00161	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CX3CR1—atherosclerosis	0.000105	0.0016	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CASR—atherosclerosis	0.000105	0.0016	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CX3CL1—atherosclerosis	0.000102	0.00157	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HRH1—atherosclerosis	0.000102	0.00157	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HRH1—atherosclerosis	9.99e-05	0.00153	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CNR2—atherosclerosis	9.93e-05	0.00152	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	9.74e-05	0.00149	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CNR2—atherosclerosis	9.72e-05	0.00149	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	9.53e-05	0.00146	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—AGT—atherosclerosis	9.01e-05	0.00138	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—AGT—atherosclerosis	8.81e-05	0.00135	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CCL3—atherosclerosis	8.54e-05	0.00131	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—CCR2—atherosclerosis	8.51e-05	0.00131	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—EDNRA—atherosclerosis	8.51e-05	0.00131	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CCL3—atherosclerosis	8.35e-05	0.00128	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—F2—atherosclerosis	8.32e-05	0.00128	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—EDNRA—atherosclerosis	8.32e-05	0.00128	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—CCR2—atherosclerosis	8.32e-05	0.00128	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—GHRL—atherosclerosis	8.29e-05	0.00127	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—F2—atherosclerosis	8.14e-05	0.00125	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—GHRL—atherosclerosis	8.11e-05	0.00124	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—APOA4—atherosclerosis	8.02e-05	0.00123	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—APOA4—atherosclerosis	7.84e-05	0.0012	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—EDNRA—atherosclerosis	7.72e-05	0.00119	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CCR2—atherosclerosis	7.72e-05	0.00119	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	7.7e-05	0.00118	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—EDNRA—atherosclerosis	7.56e-05	0.00116	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CCR2—atherosclerosis	7.56e-05	0.00116	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	7.53e-05	0.00116	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—GHRL—atherosclerosis	7.53e-05	0.00116	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—CCL2—atherosclerosis	7.42e-05	0.00114	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCL4—atherosclerosis	7.39e-05	0.00113	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—GHRL—atherosclerosis	7.36e-05	0.00113	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—GSTM1—atherosclerosis	7.28e-05	0.00112	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—KNG1—atherosclerosis	7.28e-05	0.00112	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—CCL2—atherosclerosis	7.26e-05	0.00111	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—AGTR1—atherosclerosis	7.23e-05	0.00111	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCL4—atherosclerosis	7.22e-05	0.00111	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—GSTM1—atherosclerosis	7.18e-05	0.0011	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—KNG1—atherosclerosis	7.12e-05	0.00109	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—AGTR1—atherosclerosis	7.07e-05	0.00109	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—APOA2—atherosclerosis	6.9e-05	0.00106	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—APOA2—atherosclerosis	6.75e-05	0.00104	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—KNG1—atherosclerosis	6.61e-05	0.00101	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—UTS2—atherosclerosis	6.58e-05	0.00101	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—AGTR1—atherosclerosis	6.57e-05	0.00101	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—KNG1—atherosclerosis	6.46e-05	0.000992	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—UTS2—atherosclerosis	6.44e-05	0.000988	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—AGTR1—atherosclerosis	6.42e-05	0.000986	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CX3CR1—atherosclerosis	6.31e-05	0.000968	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CASR—atherosclerosis	6.31e-05	0.000968	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CX3CL1—atherosclerosis	6.19e-05	0.00095	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CX3CR1—atherosclerosis	6.17e-05	0.000947	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CASR—atherosclerosis	6.17e-05	0.000947	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—EDN1—atherosclerosis	6.13e-05	0.000941	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—CCL5—atherosclerosis	6.08e-05	0.000934	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CX3CL1—atherosclerosis	6.05e-05	0.000929	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—EDN1—atherosclerosis	6e-05	0.00092	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—CCL5—atherosclerosis	5.95e-05	0.000913	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CNR2—atherosclerosis	5.87e-05	0.0009	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—CXCL8—atherosclerosis	5.86e-05	0.0009	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—MMP3—atherosclerosis	5.85e-05	0.000898	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PRKCG—atherosclerosis	5.78e-05	0.000888	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CNR2—atherosclerosis	5.74e-05	0.000881	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—CXCL8—atherosclerosis	5.74e-05	0.00088	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—MMP3—atherosclerosis	5.73e-05	0.000879	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PRKCG—atherosclerosis	5.66e-05	0.000868	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—EDN1—atherosclerosis	5.57e-05	0.000854	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CCL5—atherosclerosis	5.52e-05	0.000848	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—EDN1—atherosclerosis	5.45e-05	0.000836	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CCL5—atherosclerosis	5.4e-05	0.000829	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PRKCG—atherosclerosis	5.25e-05	0.000806	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—VWF—atherosclerosis	5.23e-05	0.000803	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—APOC3—atherosclerosis	5.2e-05	0.000798	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—LDLR—atherosclerosis	5.17e-05	0.000793	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—LDLRAP1—atherosclerosis	5.16e-05	0.000792	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PRKCG—atherosclerosis	5.14e-05	0.000788	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—VWF—atherosclerosis	5.12e-05	0.000785	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—AGT—atherosclerosis	5.09e-05	0.000781	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—APOC3—atherosclerosis	5.08e-05	0.00078	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—LDLR—atherosclerosis	5.05e-05	0.000775	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCL3—atherosclerosis	5.05e-05	0.000774	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—AGT—atherosclerosis	4.98e-05	0.000764	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCL3—atherosclerosis	4.94e-05	0.000757	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PLTP—atherosclerosis	4.85e-05	0.000745	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NCF1—atherosclerosis	4.83e-05	0.000741	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NCF1—atherosclerosis	4.73e-05	0.000725	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—F2—atherosclerosis	4.7e-05	0.000722	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—AGT—atherosclerosis	4.62e-05	0.000709	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—F2—atherosclerosis	4.6e-05	0.000706	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCR2—atherosclerosis	4.56e-05	0.0007	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EDNRA—atherosclerosis	4.56e-05	0.0007	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CYBA—atherosclerosis	4.54e-05	0.000697	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—AGT—atherosclerosis	4.52e-05	0.000694	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3CG—atherosclerosis	4.5e-05	0.000691	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EDNRA—atherosclerosis	4.46e-05	0.000685	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCR2—atherosclerosis	4.46e-05	0.000685	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PLAT—atherosclerosis	4.45e-05	0.000682	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PARP1—atherosclerosis	4.45e-05	0.000682	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GHRL—atherosclerosis	4.45e-05	0.000682	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CYBA—atherosclerosis	4.44e-05	0.000682	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3CG—atherosclerosis	4.4e-05	0.000676	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PLAT—atherosclerosis	4.35e-05	0.000667	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PARP1—atherosclerosis	4.35e-05	0.000667	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GHRL—atherosclerosis	4.35e-05	0.000667	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—F2—atherosclerosis	4.27e-05	0.000655	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ABCG8—atherosclerosis	4.21e-05	0.000646	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—LTA4H—atherosclerosis	4.21e-05	0.000646	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—F2—atherosclerosis	4.18e-05	0.000641	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3CG—atherosclerosis	4.09e-05	0.000627	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3CG—atherosclerosis	4e-05	0.000613	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—KNG1—atherosclerosis	3.9e-05	0.000599	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AGTR1—atherosclerosis	3.88e-05	0.000595	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—KNG1—atherosclerosis	3.82e-05	0.000586	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CCL2—atherosclerosis	3.81e-05	0.000584	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AGTR1—atherosclerosis	3.8e-05	0.000582	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PLG—atherosclerosis	3.78e-05	0.00058	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CCL2—atherosclerosis	3.72e-05	0.000571	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PLG—atherosclerosis	3.7e-05	0.000568	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SOCS3—atherosclerosis	3.58e-05	0.000549	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SOCS3—atherosclerosis	3.5e-05	0.000537	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MMP3—atherosclerosis	3.46e-05	0.000531	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IGF2—atherosclerosis	3.44e-05	0.000528	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MMP3—atherosclerosis	3.38e-05	0.000519	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IGF2—atherosclerosis	3.37e-05	0.000517	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—APOB—atherosclerosis	3.34e-05	0.000513	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ABCG1—atherosclerosis	3.33e-05	0.000511	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—CXCL8—atherosclerosis	3.31e-05	0.000509	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EDN1—atherosclerosis	3.29e-05	0.000505	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—APOB—atherosclerosis	3.27e-05	0.000502	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCL5—atherosclerosis	3.26e-05	0.000501	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—CXCL8—atherosclerosis	3.24e-05	0.000497	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EDN1—atherosclerosis	3.22e-05	0.000494	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCL5—atherosclerosis	3.19e-05	0.00049	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—LPL—atherosclerosis	3.19e-05	0.00049	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—LCAT—atherosclerosis	3.13e-05	0.00048	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—FABP4—atherosclerosis	3.13e-05	0.00048	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—LPL—atherosclerosis	3.12e-05	0.000479	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PRKCG—atherosclerosis	3.1e-05	0.000476	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—APOA4—atherosclerosis	3.07e-05	0.000471	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PRKCG—atherosclerosis	3.04e-05	0.000466	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SPP1—atherosclerosis	3.02e-05	0.000464	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP7A1—atherosclerosis	3.02e-05	0.000463	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CXCL8—atherosclerosis	3.01e-05	0.000462	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SPP1—atherosclerosis	2.96e-05	0.000454	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CXCL8—atherosclerosis	2.94e-05	0.000452	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PDGFB—atherosclerosis	2.8e-05	0.000429	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP27A1—atherosclerosis	2.79e-05	0.000428	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PDGFB—atherosclerosis	2.74e-05	0.00042	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AGT—atherosclerosis	2.73e-05	0.000419	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—LEP—atherosclerosis	2.67e-05	0.00041	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—APOE—atherosclerosis	2.67e-05	0.00041	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AGT—atherosclerosis	2.67e-05	0.00041	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CAV1—atherosclerosis	2.65e-05	0.000407	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—APOA1—atherosclerosis	2.64e-05	0.000406	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	2.64e-05	0.000406	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—APOA2—atherosclerosis	2.64e-05	0.000406	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ALOX15—atherosclerosis	2.64e-05	0.000406	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	2.64e-05	0.000406	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—LEP—atherosclerosis	2.62e-05	0.000402	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—APOE—atherosclerosis	2.62e-05	0.000402	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ABCG5—atherosclerosis	2.61e-05	0.000401	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CAV1—atherosclerosis	2.59e-05	0.000398	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—APOA1—atherosclerosis	2.59e-05	0.000397	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ESR1—atherosclerosis	2.55e-05	0.000392	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—F2—atherosclerosis	2.52e-05	0.000387	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—LPA—atherosclerosis	2.52e-05	0.000387	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ESR1—atherosclerosis	2.5e-05	0.000383	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—F2—atherosclerosis	2.47e-05	0.000379	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—BGN—atherosclerosis	2.44e-05	0.000375	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—APOA5—atherosclerosis	2.42e-05	0.000371	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3CG—atherosclerosis	2.41e-05	0.00037	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3CG—atherosclerosis	2.36e-05	0.000362	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	2.33e-05	0.000357	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—MAPK3—atherosclerosis	2.31e-05	0.000355	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—INS—atherosclerosis	2.29e-05	0.000351	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—MAPK3—atherosclerosis	2.26e-05	0.000347	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCL2—atherosclerosis	2.25e-05	0.000345	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ALOX5—atherosclerosis	2.25e-05	0.000345	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—INS—atherosclerosis	2.24e-05	0.000343	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IGF1—atherosclerosis	2.21e-05	0.000339	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCL2—atherosclerosis	2.2e-05	0.000338	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IGF1—atherosclerosis	2.16e-05	0.000332	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SERPINE1—atherosclerosis	2.1e-05	0.000322	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SERPINE1—atherosclerosis	2.05e-05	0.000315	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NAMPT—atherosclerosis	2.02e-05	0.000309	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NOS3—atherosclerosis	2e-05	0.000308	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—LIPC—atherosclerosis	2e-05	0.000307	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—APOC3—atherosclerosis	1.99e-05	0.000305	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—LDLR—atherosclerosis	1.98e-05	0.000304	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NOS3—atherosclerosis	1.96e-05	0.000301	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CETP—atherosclerosis	1.93e-05	0.000297	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SCARB1—atherosclerosis	1.85e-05	0.000284	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CXCL8—atherosclerosis	1.78e-05	0.000273	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HMGCR—atherosclerosis	1.75e-05	0.000268	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CXCL8—atherosclerosis	1.74e-05	0.000267	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—AKT1—atherosclerosis	1.72e-05	0.000264	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—IL6—atherosclerosis	1.69e-05	0.000259	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—AKT1—atherosclerosis	1.68e-05	0.000258	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—IL6—atherosclerosis	1.65e-05	0.000254	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MMP9—atherosclerosis	1.61e-05	0.000247	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NFKB1—atherosclerosis	1.59e-05	0.000244	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MMP9—atherosclerosis	1.57e-05	0.000241	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MAPK8—atherosclerosis	1.56e-05	0.00024	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—AKT1—atherosclerosis	1.56e-05	0.000239	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ABCA1—atherosclerosis	1.56e-05	0.000239	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NFKB1—atherosclerosis	1.56e-05	0.000239	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MAPK8—atherosclerosis	1.53e-05	0.000235	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—AKT1—atherosclerosis	1.53e-05	0.000234	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—VEGFA—atherosclerosis	1.44e-05	0.000222	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—STAT3—atherosclerosis	1.43e-05	0.000219	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—VEGFA—atherosclerosis	1.41e-05	0.000217	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—STAT3—atherosclerosis	1.4e-05	0.000215	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MAPK3—atherosclerosis	1.37e-05	0.00021	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HMOX1—atherosclerosis	1.34e-05	0.000205	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MAPK3—atherosclerosis	1.34e-05	0.000205	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TGFB1—atherosclerosis	1.33e-05	0.000203	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TGFB1—atherosclerosis	1.3e-05	0.000199	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—APOB—atherosclerosis	1.28e-05	0.000196	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTM1—atherosclerosis	1.25e-05	0.000191	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—LPL—atherosclerosis	1.22e-05	0.000188	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GPX1—atherosclerosis	1.19e-05	0.000183	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CD36—atherosclerosis	1.16e-05	0.000178	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—MTHFR—atherosclerosis	1.1e-05	0.000169	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PPARA—atherosclerosis	1.08e-05	0.000166	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AGT—atherosclerosis	1.05e-05	0.00016	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—APOE—atherosclerosis	1.02e-05	0.000157	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CAV1—atherosclerosis	1.02e-05	0.000156	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—APOA1—atherosclerosis	1.01e-05	0.000155	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IL6—atherosclerosis	9.99e-06	0.000153	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IL6—atherosclerosis	9.77e-06	0.00015	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3CG—atherosclerosis	9.25e-06	0.000142	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AKT1—atherosclerosis	9.21e-06	0.000141	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AKT1—atherosclerosis	9.01e-06	0.000138	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PPARG—atherosclerosis	8.92e-06	0.000137	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—INS—atherosclerosis	8.75e-06	0.000134	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ALB—atherosclerosis	8.02e-06	0.000123	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NOS3—atherosclerosis	7.68e-06	0.000118	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PTGS2—atherosclerosis	7.02e-06	0.000108	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AKT1—atherosclerosis	3.53e-06	5.41e-05	CbGpPWpGaD
